Stock Evaluator: Adlai Nortye Group Ltd. (ANL)

Adlai Nortye Group Ltd. ANL

$15.47 0.19 1.21%
September 18, 2026 9:57:17 AM EST November 10, 2021 Volume: 12,816
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.

Commentary & Analysis


Financial Summary

Share Statistics ANL Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $984.0 $272.4 45%
Shares Out (Mil) 32.0 54.6 38%
Institutional Ownership 97.8% 92.9% 75%
Float (Mil) 47.3 42.3 45%
Beta 1.12 0.94 67%
Avg Daily Volume (000s) 216 526 46%
Price Change
(52-week)
753.6% 54.9% 100%
Growth ANL Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 14.1% na
Net Income (5yr) 11.3% (10.1%) 57%
EPS (5yr) 32.0% 15.4% 83
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) (22.6%) (15.6%) 29%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials ANL Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $5 $37 6%
Net Income (TTM) (Mil) ($36) ($43) 19%
EPS (TTM) ($1.111) ($1.600) 20%
Operating Cash Flow (TTM) (Mil) ($34) ($31) 12%
Net Cash Flow (TTM) (Mil) ($73) $2 16%
Long-Term Debt (Q1) (Mil) $1 $4 17%
Enterprise Value (Q1) (Mil) $70 $182 18%
Valuation ANL Industry
Median
Percentile
(All Stocks)
P/B na 2.62 na
P/E na 19.2 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.0 na
Ratios ANL Industry
Median
Percentile
(All Stocks)
Gross Margin 100.0% 69.0% 96%
Net Margin (124.8%) (73.0%) 6%
ROA (43.2%) (47.7%) 13%
ROE (106.5%) (55.0%) 9%
Liabilities to Assets 124.2% 29.3% 97%
F-Score 2 2 7%

Adlai Nortye Group Ltd. did not pass any screens on 9/17/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors